Clinical update on nursing home medicine: 2010

Journal of the American Medical Directors Association

Volumn 11, Issue 8, 2010, Pages 543-566

  Messinger Rapport, Barbara J ^a   Morley, John E ^b,c   Thomas, David R ^b   Gammack, Julie K ^b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Asymptomatic bacteriuria; Dyslipidemia in heart failure; Dysphagia; Insomnia; Management of depression; Noncognitive aspects of dementia; Polypharmacy; Treating heart failure

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; BILE ACID SEQUESTRANT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; COLESTYRAMINE; DIGOXIN; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESZOPICLONE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; MEMANTINE; NICOTINIC ACID; PHENYTOIN; RAMELTEON; ROSUVASTATIN; TRAZODONE; UNINDEXED DRUG; VALPROIC ACID; ZALEPLON;

ABDOMINAL PAIN; AMNESIA; ANGIONEUROTIC EDEMA; ANOREXIA; ARTICLE; BACTERIURIA; BLEEDING; CARDIAC RESYNCHRONIZATION THERAPY; CHOLECYSTITIS; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DEMENTIA; DEPRESSION; DIETARY INTAKE; DIZZINESS; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG THERAPY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPHAGIA; EDEMA; EXERCISE; FATIGUE; FLUSHING; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INSOMNIA; INSULIN RESISTANCE; KIDNEY DISEASE; LIVER FUNCTION TEST; LONG TERM CARE; MYALGIA; MYOPATHY; NAUSEA; NIGHTMARE; NURSING HOME; POLYPHARMACY; RISK ASSESSMENT; SIDE EFFECT; TASTE DISORDER; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; WEIGHT REDUCTION;

EID: 77957243203     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2010.08.007     Document Type: Article

References (318)

1. Messinger-Rapport B.J., Thomas D.R., Gammack J.K., Morley J.E. Clinical update on nursing home medicine: 2009. J Am Med Dir Assoc 2009, 10:530-553.
2. Messinger-Rapport B.J., Thomas D.R., Gammack J.K., Morley J.E. Clinical update on nursing home medicine: 2008. J Am Med Dir Assoc 2008, 9:460-475.
3. Messinger-Rapport B.J., Morley J.E., Thomas D.R., Gammack J.K. Intensive session: New approaches to medical issues in long-term care. J Am Med Dir Assoc 2007, 8:421-433.
4. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 2008, 359:2195-2207.
5. Knopp R.H., D'Emden M., Smilde J.G., Pocock S.J. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes. Diabetes Care 2006, 29:1478-1485.
6. Flather M.D., Shibata M.C., Coats A.J.S., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (seniors). Eur Heart J 2005, 26:215-225.
7. Morley J.E. Caring for the vulnerable elderly: Are available quality indicators appropriate?. J Am Med Dir Assoc 2008, 9:1-3.
8. Zarowitz B.J., Aronow W.S., Hollenack K., O'Shea T. The application of evidence-based principles of care in older persons (issue 2): Management of lipid disorders. J Am Med Dir Assoc 2006, 7:173-179.
9. Joseph J., Koka M., Aronow W.S. Prevalence of a hemoglobin A1c less than 7.0%, of a blood pressure less than 130/80 mm Hg, and of a serum low-density lipoprotein cholesterol less than 100 mg/dL in older patients with diabetes mellitus in an academic nursing home. J Am Med Dir Assoc 2008, 9:51-54.
10. Koka M., Joseph J., Aronow W.S. Prevalence of adequate and of optimal control of serum low-density lipoprotein cholesterol in an academic nursing home. J Am Med Dir Assoc 2007, 8:604-606.
11. Joseph J., Koka M., Aronow W.S. Prevalence of use of antiplatelet drugs, beta blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in older patients with coronary artery disease in an academic nursing home. J Am Med Dir Assoc 2008, 9:124-127.
12. National Heart Lung and Blood Institute. Risk assessment tool for estimating your 10-year risk of having a heart attack. Healthy People 2010 Gateway. Available at: Accessed June 12, 2010. http://hp2010.nhlbihin.net/atpiii/calculator.asp.
13. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497.
14. Grundy S.M., Cleeman J.I., Merz C.N.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program adult treatment panel III guidelines. Circulation 2004, 110:227-239.
15. Glynn R.J., Koenig W., Nordestgaard B.G., et al. Rosuvastatin for primary prevention in older persons with elevated c-reactive protein and low to average low-density lipoprotein cholesterol levels: Exploratory analysis of a randomized trial. Ann Intern Med 2010, 152:488-496. W174.
16. Mora S., Glynn R.J., Hsia J., et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity c-reactive protein or dyslipidemia: Results from the justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin (jupiter) and meta-analysis of women from primary prevention trials. Circulation 2010, 121:1069-1077.
17. Ahmed W., Khan N., Glueck C.J., et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009, 153:11-16.
18. Lee P., Greenfield J.R., Campbell L.V. Vitamin D insufficiency-a novel mechanism of statin-induced myalgia?. Clin Endocrinol 2009, 71:154-155.
19. Kastelein J.J.P., Akdim F., Stroes E.S.G., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431-1443.
20. Schering-Plough, Merck. Improve-it: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin (study p04103am3) nct00202878. Available at: Accessed March 31, 2010. http://www.clinicaltrials.gov/.
21. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
22. Taylor A.J., Villines T.C., Stanek E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361(22):2113-2122.
23. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.
24. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the field study): Randomised controlled trial. Lancet 2005, 366:1849-1861.
25. Nilsson P.M. ACCORD and risk-factor control in type 2 diabetes. N Engl J Med 2010, 362:1628-1630.
26. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574. The ACCORD Study Group.
27. Haim M., Benderly M., Tanne D., et al. C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease. Am Heart J 2007, 154:1095-1101.
28. Goldenberg I., Boyko V., Tennenbaum A., et al. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial. Arch Intern Med 2009, 169:508-514.
29. Rifkind B.M., Rifkind B.M. The lipid research clinics coronary primary prevention trial. Drugs 1986, 31:53-60.
30. The LRC coronary primary prevention trial results. JAMA 1984, 251:365-374. Lipid Research Clinics Program.
31. Levy R.I. Report on the lipid research clinic trials. Eur Heart J 1987, 8:45-53.
32. The lipid research clinics coronary primary prevention trial. Results of 6 years of post-trial follow-up. The lipid research clinics investigators. Arch Intern Med 1992, 152:1399-1410. Anonymous.
33. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389. Scandinavian Simvastatin Survival Study Group.
34. Whitney E.J., Krasuski R.A., Personius B.E., et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: Effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005, 142:95-104.
35. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (jelis): A randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
36. Hooper L., Thompson R.L., Harrison R.A., et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev 2004, (4):CD003177.
37. Dijkstra S.C., Brouwer I.A., van Rooij F.J., et al. Intake of very long chain n-3 fatty acids from fish and the incidence of heart failure: The Rotterdam Study. Eur J Heart Fail 2009, 11:922-928.
38. Levitan E.B., Wolk A., Mittleman M.A. Fish consumption, marine omega-3 fatty acids, and incidence of heart failure: A population-based prospective study of middle-aged and elderly men. Eur Heart J 2009, 30:1495-1500.
39. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154-e235.
40. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 2006, 12:10-38. Heart Failure Society of America.
41. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, International Society for Heart and Lung Transplantation, Hunt SA, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. J Am Coll Cardiol 2009, 53:e1-e90.
42. Ahmed A., Jones L., Hays C.I. Defeat heart failure: Assessment and management of heart failure in nursing homes made easy. J Am Med Dir Assoc 2008, 9:383-389.
43. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ace inhibitor trials. JAMA 1995, 273:1450-1456.
44. McMurray J. Major beta blocker mortality trials in chronic heart failure: A critical review. Heart 1999, 82S(IV):14-22.
45. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999, 341:709-717.
46. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-the Losartan Heart Failure Survival Study Elite II. Lancet 2000, 355:1582-1587.
47. Dulin B.R., Haas S.J., Abraham W.T., Krum H. Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials. Am J Cardiol 2005, 95:896-898.
48. Hauptman P.J., Rich M.W., Heidenreich P.A., et al. The heart failure clinic: A consensus statement of the Heart Failure Society of America. J Card Fail 2008, 14:801-815.
49. Bursi F., Weston S.A., Redfield M.M., et al. Systolic and diastolic heart failure in the community. JAMA 2006, 296:2209-2216.
50. Tehrani F., Phan A., Chien C.V., et al. Value of medical therapy in patients >80 years of age with heart failure and preserved ejection fraction. Am J Cardiol 2009, 103:829-833.
51. Ahmed A., Rich M.W., Fleg J.L., et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: The ancillary digitalis investigation group trial. Circulation 2006, 114:397-403.
52. Ahmed A., Rich M.W., Love T.E., et al. Digoxin and reduction in mortality and hospitalization in heart failure: A comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006, 27:178-186.
53. Aronow W.S. Appropriate use of digoxin in treating older nursing home patients with heart failure. J Am Med Dir Assoc 2006, 7:604-606.
54. Chun J., Chodosh J. Controversy in heart failure management: Digoxin use in the elderly. J Am Med Dir Assoc 2006, 7:581-586.
55. Joseph J., Koka M., Aronow W.S. Prevalence of moderate and severe renal insufficiency in older persons with hypertension, diabetes mellitus, coronary artery disease, peripheral arterial disease, ischemic stroke, or congestive heart failure in an academic nursing home. J Am Med Dir Assoc 2008, 9:257-259.
56. Komajda M., McMurray J.J., Beck-Nielsen H., et al. Heart failure events with rosiglitazone in type 2 diabetes: Data from the record clinical trial. Eur Heart J 2010, 31:824-831.
57. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
58. Gislason G.H., Rasmussen J.N., Abildstrom S.Z., et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009, 169:141-149.
59. Page J., Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An underrecognized public health problem. Arch Intern Med 2000, 160:777-784.
60. Kuenzli A., Bucher H.C., Anand I., et al. Meta-analysis of combined therapy with angiotensin receptor antagonists versus ace inhibitors alone in patients with heart failure. PLoS One 2010, 5:e9946.
61. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The charm-added trial. Lancet 2003, 362:767-771.
62. Mann J.F., Schmieder R.E., McQueen M., et al. A multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study).
63. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.
64. Ahmed A., Jones L., Hays C.I. Assessment and management of heart failure in nursing homes made easy. J Am Med Dir Assoc 2008, 9:383-389. DEFEAT heart failure.
65. Hoffman R., Psaty B., Kronmal R. Modifiable risk factors for incident heart failure in the coronary artery surgery study. Arch Intern Med 1994, 154:417-423.
66. Lee D.S., Gona P., Vasan R.S., et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: Insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 2009, 119:3070-3077.
67. Nicolls M.R. The clinical and biological relationship between type II diabetes mellitus and Alzheimer's disease [review]. Curr Alzheimer Res 2004, 1:47-54.
68. Velagaleti R.S., Massaro J., Vasan R.S., et al. Relations of lipid concentrations to heart failure incidence: The Framingham Heart Study. Circulation 2009, 120:2345-2351.
69. Frankel D.S., Vasan R.S., D'Agostino R.B., et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 2009, 53:754-762.
70. Pocock SJ, McMurray JJV, Dobson J, et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (charm) programme. 2008;29:2641-2650.
71. Kalantar-Zadeh K., Horwich T.B., Oreopoulos A., et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care 2007, 10:433-442.
72. von Haehling S., Lainscak M., Springer J., Anker S.D. Cardiac cachexia: A systematic overview. Pharmacol Ther 2009, 121:227-252.
73. Rodondi N., Bauer D.C., Cappola A.R., et al. Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health Study. J Am Coll Cardiol 2008, 52:1152-1159.
74. Davis B.R., Piller L.B., Cutler J.A., et al. Role of diuretics in the prevention of heart failure: The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 2006, 113:2201-2210.
75. Bulpitt C., Fletcher A., Beckett N., et al. Hypertension in the very elderly trial (HYVET): Protocol for the main trial. Drugs Aging 2001, 18:151-164.
76. Levitan E.B., Wolk A., Mittleman M.A. Relation of consistency with the dietary approaches to stop hypertension diet and incidence of heart failure in men aged 45 to 79 years. Am J Cardiol 2009, 104:1416-1420.
77. Levitan E.B., Wolk A., Mittleman M.A. Consistency with the dash diet and incidence of heart failure. Arch Intern Med 2009, 169:851-857.
78. Nettleton J.A., Steffen L.M., Loehr L.R., et al. Incident heart failure is associated with lower whole-grain intake and greater high-fat dairy and egg intake in the Atherosclerosis Risk in Communities (ARIC) study. J Am Diet Assoc 2008, 108:1881-1887.
79. Yamagishi K., Iso H., Date C., et al. Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC (Japan Collaborative Cohort Study for Evaluation Of Cancer Risk) study. J Am Coll Cardiol 2008, 52:988-996.
80. Holick M.F. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006, 81:353-373.
81. Go A.S., Lee W.Y., Yang J., et al. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 2006, 296:2105-2111.
82. Ray J.G., Gong Y., Sykora K., Tu J.V. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005, 165:62-67.
83. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-2261.
84. Tavazzi L., Maggioni A.P., Marchioli R., et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231-1239.
85. Ahmed H.N., Levitan E.B., Wolk A., Mittleman M.A. Coffee consumption and risk of heart failure in men: An analysis from the cohort of Swedish men. Am Heart J 2009, 158:667-672.
86. Hasan A. Coffee, caffeine, and risk of hospitalization for arrhythmias. Paper presented at: Conference on Cardiovascular Disease Epidemiology and Prevention, March 2-5, 2010; San Francisco, CA.
87. Maisel W.H., Stevenson L.W. Atrial fibrillation in heart failure: Epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003, 91:2D-8D.
88. Tavazzi L., Maggioni A.P., Marchioli R., et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008, 372(9645):1223-1230.
89. Calvert M.J., Freemantle N., Cleland J.G. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail 2005, 7:243-251.
90. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005, 352:1539-1549.
91. Foley P.W.X., Chalil S., Khadjooi K., et al. Long-term effects of cardiac resynchronization therapy in octogenarians: A comparative study with a younger population. Europace 2008, 10:1302-1307.
92. Moss A.J., Hall W.J., Cannom D.S., et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009, 361:1329-1338.
93. Cheng J., Montalto M., Leff B. Hospital at home. Clin Geriatr Med 2009, 25:79-91. vi.
94. Tibaldi V., Isaia G., Scarafiotti C., et al. Hospital at home for elderly patients with acute decompensation of chronic heart failure: A prospective randomized controlled trial. Arch Intern Med 2009, 169:1569-1575.
95. Barents M., Hillege H.H., van der Horst I.C., et al. Bnp and nt-probnp, predictors of 1-year mortality in nursing home residents. J Am Med Dir Assoc 2008, 9:580-585.
96. Pfisterer M., Buser P., Rickli H., et al. Bnp-guided vs symptom-guided heart failure therapy: The trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial. JAMA 2009, 301:383-392.
97. Bhardwaj A., Rehman S.U., Mohammed A., et al. Design and methods of the pro-b type natriuretic peptide outpatient tailored chronic heart failure therapy (PROTECT) study. Am Heart J 2010, 159:532-538. e531.
98. Packer M., O'Connor C.M., Ghali J.K., et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996, 335(15):1107-1114.
99. Christensen M.D., White H.K. Dementia assessment and management. J Am Med Dir Assoc 2006, 7:109-118.
100. Mansdorf I.J., Harrington M., Lund J., Wohl N. Neuropsychological testing in skilled nursing facilities: The failure to confirm diagnoses of dementia. J Am Med Dir Assoc 2008, 9:271-274.
101. Cruz-Oliver D.M., Morley J.E. Early detection of cognitive impairment: Do screening tests help?. J Am Med Dir Assoc 2010, 11:1-6.
102. Tariq S.H., Tumosa N., Chibnall J.T., et al. Comparison of the Saint Louis University mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder-a pilot study. Am J Geriatr Psychiatry 2006, 14:900-910.
103. Banks W.A., Morley J.E. Memories are made of this: Recent advances in understanding cognitive impairments and dementia. J Gerontol A Biol Sci Med Sci 2003, 58:314-321.
104. Joshi S., Morley J.E. Cognitive impairment. Med Clin North Am 2006, 90:769-787.
105. Thakur M., Blazer D.G. Depression in long-term care. J Am Med Dir Assoc 2008, 9:82-87.
106. Karakaya M.G., Bilgin S.C., Ekici G., et al. Functional mobility, depressive symptoms, level of independence, and quality of life of the elderly living at home and in the nursing home. J Am Med Dir Assoc 2009, 10:662-666.
107. Volicer L. Behaviors in advanced dementia. J Am Med Dir Assoc 2009, 10:146.
108. Volicer L. Is aggression a common symptom of dementia?. J Am Med Dir Assoc 2008, 9:532.
109. Kverno K.S., Black B.S., Blass D.M., et al. Neuropsychiatric symptom patterns in hospice-eligible nursing home residents with advanced dementia. J Am Med Dir Assoc 2008, 9:509-515.
110. Smith D.A. Behavioral problems and symptoms in dementia. J Am Med Dir Assoc 2008, 9:622-625.
111. Cohen-Mansfield J., Jensen B. Assessment and treatment approaches for behavioral disturbances associated with dementia in the nursing home: Self-reports of physicans' practices. J Am Med Dir Assoc 2008, 9:406-413.
112. Ishii S., Weintraub N., Mervis J.R. Apathy: A common psychiatric syndrome in the elderly. J Am Med Dir Assoc 2009, 10:381-393.
113. Volicer L., Van der Steen J.T., Frijters D.H. Modifiable factors related to abusive behaviors in nursing home residents with dementia. J Am Med Dir Assoc 2009, 10:617-622.
114. Bharucha A.J., Vasilescu M., Dew M.A., et al. Prevalence of behavioral symptoms: Comparison of the minimum data set assessments with research instruments. J Am Med Dir Assoc 2008, 9:244-250.
115. Leibovici A. Beyond the minimum data set: Measuring disruptive behaviors in nursing home residents. Do we need better psychometrics or simply different metrics?. J Am Med Dir Assoc 2008, 9:211-212.
116. Myers R.M., Reger L. Diabetes management in long-term care facilities: A practical guide. J Am Med Dir Assoc 2009, 10:589.
117. Feldman S.M., Rosen R., DeStasio J. Status of diabetes management in the nursing home setting in 2008: A retrospective chart review and epidemiology study of diabetic nursing home residents and nursing home initiatives in diabetes management. J Am Med Dir Assoc 2009, 10:354-360.
118. Mooradian A.D., Perryman K., Fitten J., et al. Cortical function in elderly non-insulin dependent diabetic patients. Behavioral and electrophysiologic studies. Arch Intern Med 1988, 148:2369-2372.
119. Morley J.E., Mooradian A.D., Rosenthal M.J., Kaiser F.E. Diabetes mellitus in elderly patients. Is it different?. Am J Med 1987, 83:533-544.
120. Farr S.A., Yamada K.A., Butterfield D.A., et al. Obesity and hypertriglyceridemia produce cognitive impairment. Endocrinology 2008, 149:2628-2636.
121. Banks W.A., Coon A.B., Robinson S.M., et al. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 2004, 53:1253-1260.
122. DiFrancesco V., Barazzoni R., Bissoli L., et al. The quantity of meal fat influences the profile of postprandial hormones as well as hunger sensation in healthy elderly people. J Am Med Dir Assoc 2010, 11:188-193.
123. Morley J.E. Editorial: Postprandial hypotension-the ultimate Big Mac Attack. J Gerontol A Biol Sci Med Sci 2001, 56:M744-M748.
124. Morley J.E. Weight loss in older persons: New therapeutic approaches. Curr Pharm Des 2007, 13:3637-3647.
125. Omran M.L., Morley J.E. Assessment of protein energy malnutrition in older persons. Part I: History, examination, body composition, and screening tools. Nutrition 2000, 16:50-63.
126. Morley J.E., Levine A.S. The pharmacology of eating behavior. Annu Rev Pharmacol Toxicol 1985, 25:127-146.
127. Flaherty J.H., Shay K., Weir C., et al. The development of a mental status vital sign for use across the spectrum of care. J Am Med Dir Assoc 2009, 10:379-380. VA Delirium Working Group.
128. Eeles E., Rockwood K. Delirium in the long-term care setting: Clinical and research challenges. J Am Med Dir Assoc 2008, 9:157-161.
129. Flaherty J.H., Rudolph J., Shay K., et al. Why assessment of mental status should be the sixth vital sign. J Am Med Dir Assoc 2007, 8:273-275. Delirium is a serious and under-recognized problem.
130. Jones R.N., Kiely D.K., Marcantonio E.R. Prevalence of delirium on admission to postacute care is associated with a higher number of nursing home deficiencies. J Am Med Dir Assoc 2010, 11:253-256.
131. Voyer P., Richard S., Doucet L., Carmichael P.H. Detecting delirium and subsyndromal delirium using different diagnostic criteria among demented long-term care residents. J Am Med Dir Assoc 2009, 10:181-188.
132. Laurila J.V., Strandberg T.E., Tilvis R.S., Pitkala K.H. Detecting delirium using different diagnostic criteria among long-term care residents. J Am Med Dir Assoc 2009, 10:511-512.
133. Yeh S.S., Blackwood K., Schuster M.W. The cytokine basis of cachexia and its treatment: Are they ready for prime time?. J Am Med Dir Assoc 2008, 9:219-236.
134. Banks W.A., Farr S.A., La Scola M.E., Morley J.E. Intravenous human interleukin-1 alpha impairs memory processing in mice: Dependence on blood-brain barrier transport into posterior division of the septum. J Pharmacol Exp Ther 2001, 299:536-541.
135. Thomas D.R., Cote T.R., Lawhorne L., et al. Understanding clinical dehydration and its treatment. J Am Med Dir Assoc 2008, 9:292-301. Dehydration Council.
136. Crecelius C. Dehydration: Myth and reality. J Am Med Dir Assoc 2008, 9:287-288.
137. Albert S.M. Behavioral interventions to reduce risk of falls in nursing home residents. J Am Med Dir Assoc 2009, 10:593-594.
138. Morley J.E. Falls and fractures. J Am Med Dir Assoc 2007, 8:276-278.
139. Cervo F.A., Bruckenthal P., Chen J.J., et al. Pain assessment in nursing home residents with dementia: Psychometric properties and clinical utility of the CNA Pain Assessment Tool (CPAT). J Am Med Dir Assoc 2009, 10:505-510.
140. Husebo B.S., Strand L.I., Moe-Nilssen R., et al. Who suffers most? Dementia and pain in nursing home patients: A cross-sectional study. J Am Med Dir Assoc 2008, 9:427-433.
141. Tait R.C., Chibnall J.T. Under-treatment of pain in dementia: Assessment is key. J Am Med Dir Assoc 2008, 9:372-374.
142. Leone A.F., Standoli F., Hirth V. Implementing a pain management program in a long-term care facility using a quality improvement approach. J Am Med Dir Assoc 2009, 10:67-73.
143. Keeney C.E., Scharfenberger J.A., O'Brien J.G., et al. Initiating and sustaining a standardized pain management program in long-term care facilities. J Am Med Dir Assoc 2008, 9:347-353.
144. Iraqi A., Hughes T.L. Nightmares and memantine: A case report and review of literature. J Am Med Dir Assoc 2009, 10:77-78.
145. Jalbert J.J., Eaton C.B., Miller S.C., Lapane K.L. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc 2010, 11:120-127.
146. Ozbolt L.B., Paniagua M.A., Kaiser R.M. Atypical antipsychotics for the treatment of delirious elders. J Am Med Dir Assoc 2008, 9:18-28.
147. Kales H.C., Valenstein M., Kim H.M., et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 2007, 164:1568-1576.
148. Wang P.S., Schneeweiss S., Avorn J., et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005, 353:2335-2341.
149. Schneider L.S., Tariot P.N., Dagerman K.S., et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006, 355:1525-1538.
150. Maurer I. Aripiprazole for the treatment of agitation in persons with dementia?. J Am Med Dir Assoc 2009, 10:442.
151. Rappaport S.A., Marcus R.N., Manos G., et al. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia. J Am Med Dir Assoc 2009, 10:21-27.
152. Cohen-Mansfield J., Jensen B. Nursing home physicians' knowledge of and attitudes toward nonpharmacological interventions for treatment of behavioral disturbances associated with dementia. J Am Med Dir Assoc 2008, 9:491-498.
153. Morley J.E. Managing persons with dementia in the nursing home: High touch trumps high tech. J Am Med Dir Assoc 2008, 9:139-146.
154. Banks M.R., Willoughby L.M., Banks W.A. Animal-assisted therapy and loneliness in nursing homes: Use of robotic versus living dogs. J Am Med Dir Assoc 2008, 9:173-177.
155. Morley J.E. Magic of exercise. J Am Med Dir Assoc 2008, 9:375-377.
156. Hui E.K., Rubenstein L.Z. Promoting physical activity and exercise in older adults. J Am Med Dir Assoc 2006, 7:310-314.
157. Rolland Y., Abelland van Kan G., Vellas B. Physical activity and Alzheimer's disease: From prevention to therapeutic perspectives. J Am Med Dir Assoc 2008, 9:390-405.
158. Aman E., Thomas D.R. Supervised exercise to reduce agitation in severely cognitively impaired persons. J Am Med Dir Assoc 2009, 10:271-276.
159. Hogan D.B., Bailey P., Black S., et al. Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. CMAJ 2008, 179:1019-1026.
160. Netz Y., Jacob T. Exercise and the psychological state of institutionalized elderly: A review. Percept Mot Skills 1994, 79:1107-1118.
161. Detweiler M.B., Murphy P.F., Myers L.C., Kim K.Y. Does a wander garden influence inappropriate behaviors in dementia residents?. Am J Alzheimer Dis Other Demen 2008, 23:31-45.
162. Riemersma-van der Lek R.F., Swaab D.F., Twisk J., et al. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: A randomized controlled trial. JAMA 2008, 299:2642-2655.
163. Gammack J.K., Burke J.M. Natural light exposure improves subjective sleep quality in nursing home residents. J Am Med Dir Assoc 2009, 10:440-441.
164. Locca J.F., Bula C.J., Zumbach S., Bugnon O. Pharmacological treatment of behavioral and psychological symptoms of dementia (BPSD) in nursing homes: Development of practice recommendations in a Swiss canton. J Am Med Dir Assoc 2008, 9:439-448.
165. Martinon-Torres G., Fioravanti M., Grimley E.J. Trazodone for agitation in dementia. Cochrane Database Syst Rev 2004, (4):CD004990.
166. Lonergan E., Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev 2009, (8):CD003945.
167. Dombrovski A.Y., Mulsant B.H., Ferrell R.E., et al. Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. Int Clin Psychopharmacol 2010, 25:37-45.
168. Campbell N., Ayub A., Boustani M.A., et al. Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: A meta-analysis. Clin Interv Aging 2008, 3:719-728.
169. Volicer L. Culture change for residents with dementia. J Am Med Dir Assoc 2008, 9:459.
170. Rozzini R., Trabucchi M. Managing persons with dementia in the nursing home. J Am Med Dir Assoc 2008, 9:368.
171. Cornali C., Bianchetti A., Trabucchi M. End-stage nursing home residents with dementia: Recognizing the need for palliative care. J Am Med Dir Assoc 2008, 9:281-283.
172. Miles R.W. A conversation: Polypharmacy in the nursing home. J Am Med Dir Assoc 2010, 11:296-297.
173. Gokce Kutsal Y, Barak A, Atalay A, et al. Polypharmacy in the elderly: A multicenter study. J Am Med Dir Assoc 209;10:486-490.
174. Morley J.E. Polypharmacy in the nursing home. J Am Med Dir Assoc 2009, 10:289-291.
175. Rowland F.N., Cowles M., Dickstein C., Katz P.R. Impact of medical director certification on nursing home quality of care. J Am Med Dir Assoc 2009, 10:431-435.
176. Abellan van Kan G., Rolland Y.M., Morley J.E., Vellas B. Frailty: Toward a clinical definition. J Am Med Dir Assoc 2008, 9:71-72.
177. Morley J.E. Developing novel therapeutic approaches to frailty. Curr Pharm Des 2009, 15:3384-3395.
178. Abellan van Kan G., Rolland Y., Bergman H., et al. The IANA Task Force on frailty assessment of older people in clinical practice. J Nutr Health Aging 2008, 12:29-37.
179. Morley J.E. Weight loss in older persons: New therapeutic approaches. Curr Pharm Des 2007, 13:3637-3647.
180. Morley J.E. Anorexia, sarcopenia, and aging. Nutrition 2001, 17:660-663.
181. Landi F., Russo A., Liperoti R., et al. Anorexia, physical function, and incident disability among the frail elderly population: Results from the ilSIRENTE study. J Am Med Dir Assoc 2010, 11:268-274.
182. Drinka P.J. Medications prescribed by specialists in nursing homes. J Am Med Dir Assoc 2008, 9:137-138.
183. Flaherty J.H., Perry H.M., Lynchard G.S., Morley J.E. Polypharmacy and hospitalization among older home care patients. J Gerontol A Biol Sci Med Sci 2000, 55:M554-M559.
184. Kolanowski A., Fick D.M., Campbell J., et al. A preliminary study of anticholinergic burden and relationship to a quality of life indicator, engagement in activities, in nursing home residents with dementia. J Am Med Dir Assoc 2009, 10:252-257.
185. Verrue C.L., Mehuys E., Somers A., et al. Medication administration in nursing homes: Pharmacists' contribution to error prevention. J Am Med Dir Assoc 2010, 11:275-283.
186. Chan S. Factors associated with the use of electronic information systems for drug dispensing and medication administration records in nursing homes. J Am Med Dir Assoc 2008, 9:414-421.
187. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled trial. Lancet 2002, 360:1623-1630. PROSPER Study Group.
188. Morley J.E. Hypertension: Is it overtreated in the elderly?. J Am Med Dir Assoc 2010, 11:147-152.
189. Aronow W.S. Hypertension in the nursing home. J Am Med Dir Assoc 2008, 9:486-490.
190. Beckett N.S., Peters R., Fletcher A.E., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008, 358:1887-1898. HYVET Study Group.
191. Iwanczyk L., Weintraub N.T., Rubenstein L.Z. Orthostatic hypotension in the nursing home setting. J Am Med Dir Assoc 2006, 7:163-167.
192. Morley J.E. Falls and fractures. J Am Med Dir Assoc 2007, 8:276-278.
193. Morley J.E. Hip fractures. J Am Med Dir Assoc 2010, 11:81-83.
194. Tariq S.H. Constipation in long-term care. J Am Med Dir Assoc 2007, 8:209-218.
195. Raina P., Santaguida P., Ismaila A., et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med 2008, 148:379-397.
196. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006, (1):CD005593.
197. Clegg A., Bryant J., Nicholson T., et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: Rapid and systematic review. Health Technol Assess 2001, 5:1-137.
198. Lanctôt K.L., Herrmann N., Yau K.K., et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003, 169:557-564.
199. Dahl L.J., Wright R., Xiao A., et al. Quality improvement in long-term care: The psychotropic assessment tool (PAT). J Am Med Dir Assoc 2008, 9:676-683.
200. Morley J.E. Caring for the vulnerable elderly: Are available quality indicators appropriate?. J Am Med Dir Assoc 2008, 9:1-3.
201. Morley J.E. Rapid cycles (continuous quality improvement), an essential part of the medical director's role. J Am Med Dir Assoc 2008, 9:535-538.
202. Morley J.E. Phronesis and the medical director. J Am Med Dir Assoc 2009, 10:149-152.
203. Levenson S.A., Morley J.E. Evidence rocks in long-term care, but does it roll?. J Am Med Dir Assoc 2007, 8:493-501.
204. Nicolle L.E., Bradley S., Colgan R., et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005, 40:643-654.
205. Nicolle L.E., Strausbaugh L.J., Garibaldi R.A. Infections and antibiotic resistance in nursing homes. Clin Microbiol Rev 1996, 9:1-17.
206. Stevenson K.B., Moore J., Colwell H., Sleeper B. Standardized infection surveillance in long-term care: Interfacility comparisons from a regional cohort of facilities. Infect Control Hosp Epidemiol 2005, 26:231-238.
207. Nicolle L.E. Urinary tract infections in the elderly. Clin Geriatr Med 2009, 25:423-436.
208. Juthani-Mehta M., Quagliarello V., Perrelli E., et al. Clinical features to identify urinary tract infection in nursing home residents: A cohort study. J Am Geriatr Soc 2009, 57:963-970.
209. Ouslander J.G., Schapira M., Schnelle J.F., Fingold S. Pyuria among chronically incontinent but otherwise asymptomatic nursing home residents. J Am Geriatr Soc 1996, 44:420-423.
210. Ackermann R.J., Monroe P.W. Bacteremic urinary tract infection in older people. J Am Geriatr Soc 1996, 44:927-933.
211. Ducharme J., Neilson S., Ginn J.L. Can urine cultures and reagent test strips be used to diagnose urinary tract infection in elderly emergency department patients without focal urinary symptoms?. Can J Emerg Med 2007, 9:87-92.
212. Arinzon Z., Peisakh A., Shuval I., et al. Detection of urinary tract infection (UTI) in long-term care setting: Is the multireagent strip an adequate diagnostic tool?. Arch Gerontol Geriatr 2009, 48:227-231.
213. Deville W.L., Yzermans J.C., van Duijn N.P., et al. The urine dipstick test useful to rule out infections. A meta-analysis of the accuracy. BMC Urol 2004, 4:4.
214. McGeer A., Campbell B., Emori T.G., et al. Definitions of infection for surveillance in long-term care facilities. Am J Infect Control 1991, 19:1-7.
215. Vasudevan V., Thomas D.R., Flaherty J., et al. Delirium associated with urinary tract infection May 2009, American Geriatrics Society, Paper presented at, Chicago, IL.
216. Ouslander J.G., Schapira M., Schnelle J.F., et al. Does eradication of bacteriuria affect the severity of chronic urinary incontinence in nursing home residents?. Ann Intern Med 1995, 122:749-754.
217. Nicolle L.E., Bjornson J., Harding G.K.M., MacDonell J.A. Bacteriuria in elderly institutionalized men. N Engl J Med 1983, 309:1420-1426.
218. High K.P., Bradley S.F., Gravenstein S., et al. Infectious Diseases Society of America. Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. J Am Geriatr Soc 2009, 57:375-394.
219. Mari F., Matei M., Ceravolo M.G., et al. Predictive value of clinical indices in detecting aspiration in patients with neurological disorders. J Neurol Neurosurg Psychiatry 1997, 63:456-460.
220. Garon B.R., Engle M., Ormiston C. Silent aspiration: Results of 1,000 videofluoroscopic swallow evaluations. J Neurol Rehabil 1996, 10:121-126.
221. Smith C.H., Logemann J.A., Colangelo L.A., et al. Incidence and patient characteristics associated with silent aspiration in the acute care setting. Dysphagia 1999, 14:1-7.
222. Leder S.B., Sasaki C.T., Burrell M.I. Fiberoptic endoscopic evaluation of dysphagia to identify silent aspiration. Dysphagia 1998, 13:19-21.
223. Ramsey D., Smithard D., Kalra L. Silent aspiration: What do we know?. Dysphagia 2005, 20:218-225.
224. Logemann J.A. A randomized study of three interventions for aspiration of thin liquids in patients with dementia or Parkinson's disease. J Speech Lang Hear Res 2008, 51:173-183.
225. Groher M.E. Bolus management and aspiration pneumonia in patients with pseudobulbar dysphasia. Dysphasia 1987, 1:215-216.
226. DePippo K.L., Holas M.A., Reding M.J., et al. Dysphagia therapy following stroke. Neurology 1994, 44:1655-1660.
227. Wright L., Cotter D., Hickson M., Frost G. Comparison of energy and protein intakes of older people consuming a texture modified diet with a normal hospital diet. J Hum Nutr Diet 2005, 18:213-219.
228. Taylor K., Barr S. Provision of small, frequent meals does not improve energy intake of elderly residents with dysphagia who live in an extended care facility. J Am Diet Assoc 2006, 106:1115-1118.
229. Norton B., Homer-Ward M., Donnelly M.T., et al. A randomised prospective comparison of percutaneous endoscopic gastrostomy and nasogastric tube feeding after acute dysphagic stroke. Br Med J 1996, 312:13-16.
230. Bath P.M., Bath F.J., Smithard D.G. Interventions for dysphagia in acute stroke. Cochrane Database of Syst Rev 2000, (2):CD000323.
231. Mann G., Baxter K., Hankey G., et al. Treatment for swallowing disorders following acute stroke: A randomised controlled trial [abstract]. Paper presented at Stroke Society of Australia Annual Scientific Meeting September 1997.
232. Bath P.M., Bath F.J., Smithard D.G. Interventions for dysphagia in acute stroke. Cochrane Database of Syst Rev 2000, (2):CD000323.
233. Marrie T.J., Durant H., Kwan C. Nursing home-acquired pneumonia: A case-control study. J Am Geriatr Soc 1986, 34:697-702.
234. Horner J., Brazer S., Massey E. Aspiration in bilateral stroke patients: A validation study. Neurology 1993, 43:430-433.
235. Perry L., Love C.P. Screening for dysphagia and aspiration in acute stroke: A systematic review. Dysphagia 2001, 16:7-18.
236. Martino R., Pron G., Diamant N. Screening for oropharyngeal dysphagia in stroke: Insufficient evidence for guidelines. Dysphagia 2000, 15:19-30.
237. Gleeson K., Eggli D.F., Maxwell S.L. Quantitative aspiration during sleep in normal subjects. Chest 1997, 111:1266-1272.
238. Ekberg O., Feinberg M.J. Altered swallowing function in elderly patients without dysphagia: Radiologic findings in 56 cases. Aspiration. AJR Am J Roentgenol 1991, 156:1181-1184.
239. Robbins J., Hamilton J.W., Lof G.L., et al. Oropharyngeal swallowing in normal adults of different ages. Gastroenterology 1992, 103:823-829.
240. Langmore S., Terpenning M., Schork A., et al. Predictors of aspiration pneumonia: How important is dysphagia?. Dysphagia 1998, 13:69-81.
241. Martin B., Corlew M., Wood H., et al. The association of swallowing dysfunction and aspiration pneumonia. Dysphagia 1994, 9:1-6.
242. Pick N., McDonald A., Bennett N., et al. Pulmonary aspiration in a long-term care setting: Clinical and laboratory observations and an analysis of risk factors. J Am Geriatr Soc 1994, 44:763-768.
243. Croghan J., Burker E., Caplan S., et al. Pilot study of 12-month outcomes of nursing home patients with aspiration on videofluoroscopy. Dysphagia 1994, 9:141-146.
244. Langmore S.E., Terpenning M.S., Schork A., et al. Predictors of aspiration pneumonia: How important is dysphagia?. Dysphagia 1998, 13:69-81.
245. Robbins J., Genser G., Hine J., et al. Comparison of 2 interventions for liquid aspiration on pneumonia incidence: A randomized trial. Ann Intern Med 2008, 148:509-518.
246. Balan K.K., Vinjamuri S., Maltby P., et al. Gastroesophageal reflux in patients fed by percutaneous endoscopic gastrostomy (PEG): Detection by a simple scintigraphic method. Am J Gastroenterol 1998, 93:946-949.
247. Finucane T.E., Bynum J.P. Use of tube feeding to prevent aspiration pneumonia. Lancet 1996, 348:1421-1424.
248. Haddad R.Y., Thomas D.R. Enteral nutrition and tube feeding: A review of the evidence. Geriatr Clin North Am 2002, 18:867-882.
249. Campbell-Taylor I. Oropharyngeal dysphagia in long term-care: Misperceptions of treatment efficacy. J Am Med Dir Assoc 2008, 9:523-531.
250. Bonten M.J., Gaillard C.A., van der Geest S., et al. The role of intragastric acidity and stress ulcer prophylaxis on colonization and infection in mechanically ventilated ICU patients: A stratified, randomized, double blind study of sucralfate versus antacids. Am J Respir Crit Care Med 1995, 152:1825-1834.
251. Drinka P.J., Hanlon J. Aspiration of gastric contents. J Am Med Dir Assoc 2007, 8:345-346.
252. Bonten M.J., Gaillard C.A., van Tiel F.H., et al. Continuous enteral feeding counteracts preventive measures for gastric colonization in intensive care unit patients. Crit Care Med 1994, 22:939-944.
253. Yoneyama T., Yoshida M., Matsui T., et al. Oral care and pneumonia. Lancet 1999, 354:515.
254. Gillin J.C., Byerley W.F. The diagnosis and management of insomnia. New Eng J Med 1990, 322:239-248.
255. Foley D.J., Monjan A., Simonsick E.M., et al. Incidence and remission of insomnia among elderly adults: An epidemiologic study of 6,800 persons over three years. Sleep 1999, 22:S366-S372.
256. Schubert C.R., Cruickshanks K.J., Dalton D.S., et al. Prevalence of sleep problems and quality of life in an older population. Sleep 2002, 25:889-893.
257. Baber S.I., Enright P.L., Boyle P., et al. Sleep disturbances and their correlates in elderly Japanese American men residing in Hawaii. J Gerontology A Biol Sci Med Sci 2000, 55A:M406-M411.
258. Foley D.J., Monjan A.A., Brown S.L., et al. Sleep complaints among elderly persons: An epidemiologic study of three communities. Sleep 1995, 18:425-432.
259. Sukying C., Bhokakul V., Udomsubpayakul U. An epidemiological study on insomnia in an elderly Thai population. J Med Assoc Thai 2003, 86:316-324.
260. Chlu H.F.K., Leung T., Lam L.C.W., et al. Sleep problems in Chinese elderly in Hong Kong. Sleep 1999, 22:717-726.
261. Almeida O.P., Tamai S., Garrido R. Sleep complaints among the elderly: Results from a survey in a psychogeriatric outpatient clinic in Brazil. Int Psychogeriatr 1999, 11:47-56.
262. Maggi S., Langlois J.A., Minicuci N., et al. Sleep complaints in community-dwelling older persons: Prevalence, associated factors and reported causes. J Am Geriatr Soc 1998, 46:161-168.
263. Ganguli M., Reynolds C.F., Gilby J.E. Prevalence and persistence of sleep complaints in a rural older community sample: The MoVIES project. J Am Geriatr Soc 1996, 44:778-784.
264. Floyd J.A. Sleep and aging. Nurs Clin N Am 2002, 37:719-731.
265. Montgomery P. Treatments for sleep problems in elderly people. Br Med J 2002, 325:1049.
266. McCall W.V. Sleep in the elderly: Burden, diagnosis and treatment. Prim Care Companion J Clin Psychiatry 2004, 6:9-20.
267. Brassington G.S., King A.C., Bliwise D.L. Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64-99 years. J Am Geriatr Soc 2000, 48:1234-1240.
268. Onen F., Higgins S., Onen S.H. Falling-asleep-related injured falls in the elderly. J Am Med Dir Assoc 2009, 10:207-210.
269. Cricco M., Simonsick E.M., Foley D.J. The impact of insomnia on cognitive functioning in older adults. J Am Geriatr Soc 2001, 49:1185-1189.
270. Manabe K., Matsui T., Yamaya M., et al. Sleep patterns and mortality among elderly patients in a geriatric hospital. Gerontology 2000, 46:318-322.
271. Greco K.E., Deaton C., Kutner M., et al. Psychoactive medications and actigraphically scored sleep quality in frail nursing home patients. J Am Med Dir Assoc 2004, 5:223-227.
272. National Institutes of Health Consensus development conference statement: The treatment of sleep disorders of older people. March 26-28, 1990. Sleep 1991, 14:169-177.
273. Roth T., Hajak G., Üstün T.B. Consensus for the pharmacological management of insomnia in the new millennium. Int J Clin Pract 2001, 55:42-52.
274. Alessi C.A., Martin J.L., Webber A.P., et al. Randomized, controlled trial of a nonpharmacological intervention to improve abnormal sleep/wake patterns in nursing home residents. Am Geriatr Soc 2005, 53:803-810.
275. Richards K.C., Beck C., O'Sullivan P.S., Shue V.M. Effect of individualized social activity on sleep in nursing home residents with dementia. J Am Geriatr Soc 2005, 53:1510-1517.
276. Ouslander J.G., Connell B.R., Bliwise D.L., et al. A nonpharmacological intervention to improve sleep in nursing home patients: Results of a controlled clinical trial. J Am Geriatr Soc 2006, 54:38-47.
277. Hedner J., Yaeche R., Emilien G., et al. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. Int J Geriatr Psychiatry 2000, 15:704-712.
278. Ancoli-Israel S., Walsh J.K., Mangano R.M., Fujimori M. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Prim Care Companion J Clin Psychiatry 1999, 1:114-120.
279. Ancoli-Israel S., Richardson G.S., Mangano R.M., et al. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 2005, 6:107-113.
280. Shaw S.H., Curson H., Coquelin J.P. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res 1992, 20:150-161.
281. Walsh J.K., Soubrane C., Roth T. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry 2008, 16:44-57.
282. Scharf M., Erman M., Rosenberg R., et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005, 28:720-727.
283. McCall W.V., Erman M., Krystal A.D., et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006, 22:1633-1642.
284. Ancoli-Israel S., Krystal A.D., McCall W.V., et al. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep 2010, 33:225-234.
285. Roth T., Seiden D., Sainati S., et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006, 7:312-318.
286. Mini L.J., Wang-Weigand S., Zhang J. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. Am J Geriatr Pharmacother 2007, 5:177-184.
287. Roth T., Seiden D., Wang-Weigand S., Zhang J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007, 23:1005-1014.
288. Glass J., Lanctôt K.L., Herrmann N., et al. Sedative hypnotics in older people with insomnia: Meta-analysis of risks and benefits. BMJ 2005, 331:1169.
289. Scharf M., Rogowski R., Hull S., et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: A randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2008, 69:1557-1564.
290. Levin C.A., Wei W., Akincigil A., et al. Prevalence and treatment of diagnosed depression among elderly nursing home residents in Ohio. J Am Med Dir Assoc 2007, 8:585-594.
291. Damián J., Pastor-Barriuso R., Valderrama-Gama E. Descriptive epidemiology of undetected depression in institutionalized older people. J Am Med Dir Assoc 2010, 11:312-319.
292. Rovner B.W., German P.S., Brant L.J., et al. Depression and mortality in nursing homes. JAMA 1991, 265:993-996.
293. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
294. ECDEU Assessment Manual for Psychopharmacology 1976, 218-222. US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, Rockville, MD, Publication ADM 76-338. W. Guy (Ed.).
295. Montgomery S.A. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.
296. Rahman M.K., Akhtar M.J., Savla N.C., et al. A double-blind, randomized comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients. Br J Clin Pract 1991, 45:255-258.
297. Forlenza O.V., Stoppe Júnior A., Hirata E.S., Ferreira R.C. Antidepressant efficacy of sertraline and imipramine for the treatment of major depression in elderly outpatients. Sao Paulo Med J 2000, 118:99-104.
298. Bump G.M., Mulsant B.H., Pollock B.G., et al. Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depress Anxiety 2001, 13:38-44.
299. Kok R.M., Aartsen M., Nolen W.A., Heeren T. The course of adverse effects of nortriptyline and venlafaxine in elderly patients with major depression. J Am Geriatr Soc 2009, 57:2112-2117.
300. Gastó C., Navarro V., Marcos T., et al. Single-blind comparison of venlafaxine and nortriptyline in elderly major depression. J Clin Psychopharmacol 2003, 23:21-26.
301. Papakostas G.I., Fava M. A meta-analysis of clinical trials comparing milnacipran, a serotonin-norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur Neuropsychopharmacol 2007, 17:32-36.
302. Papakostas G.I., Nelson J.C., Kasper S., Möller H.J. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol 2008, 18:122-127.
303. Papakostas G.I., Thase M.E., Fava M., et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007, 62:1217-1227.
304. Bauer M., Tharmanathan P., Volz H.P., et al. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: A meta-analysis. Eur Arch Psychiatry Clin Neurosci 2009, 259:172-185.
305. Hwang J.P., Yang C.H., Tsai S.J. Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients. Int J Geriatr Psychiatry 2004, 19:189-190.
306. Oslin D.W., Ten Have T.R., Streim J.E., et al. Probing the safety of medications in the frail elderly: Evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry 2003, 64:875-882.
307. Allard P., Gram L., Timdahl K., et al. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomized 6-month comparative trial with citalopram. Int J Geriatr Psychiatry 2004, 19:1123-1130.
308. Schatzberg A.F., Kremer C., Rodrigues H.E., Murphy G.M. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002, 10:541-550.
309. Rossini D., Serretti A., Franchini L., et al. Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial. Clin Psychopharmacol 2005, 25:471-475.
310. Rush A.J., Trivedi M.H., Wisniewski S.R., et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006, 354:1231-1242.
311. Blier P., Gobbi G., Turcotte J.E., et al. Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009, 19:457-465.
312. Garakani A., Martinez J.M., Marcus S., et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol 2008, 23:269-275.
313. Mahmoud R.A., Pandina G.J., Turkoz I., et al. Risperidone for treatment-refractory major depressive disorder: A randomized trial. Ann Intern Med 2007, 147:593-602.
314. Nelson J.C., Papakostas G.I. Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009, 166:980-991.
315. Politis A.M., Papadimitriou G.N., Theleritis C.G., et al. Combination therapy with amisulpride and antidepressants: Clinical observations in case series of elderly patients with psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1227-1230.
316. Meyers B.S., Flint A.J., Rothschild A.J., et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: The study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry 2009, 66:838-847.
317. Dunlop B.W., Crits-Christoph P., Evans D.L., et al. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2007, 27:614-619.
318. Lavretsky H., Park S., Siddarth P., et al. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: A double-blind, placebo-controlled pilot trial. Am J Geriatr Psychiatry 2006, 14:181-185.